Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you’re looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive “buy” and “strong buy” ratings from Wall Street’s top-rated research analysts.

#1 – Integra Resources

NYSEMKT:ITRG
Stock Price: $0.52

(-$0.02)

PE Ratio: -1.63
Market Cap: $41.48 million
Average Trading Volume: 59,281 shares
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.96 (469.2% Upside)

$0.52-1.63: $41.48 million59,281 sharesBuy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$2.96 (469.2% Upside)

Integra Resources Corp., a mineral resources company, engages in the acquisition, exploration, and development of mineral properties in the Americas. It primarily focuses on the development of DeLamar project that consists of DeLamar and Florida Mountain gold and silver deposits comprising 790 unpatented lode, placer, and millsite claims, as well as 16 tax parcels covering an area of approximately 8,673 hectares located in the Owyhee County, south western Idaho. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

#2 – Cybin

OTCMKTS:CYBN
Stock Price: $0.52

(-$0.04)

PE Ratio: -2.26
Market Cap: $98.39 million
Average Trading Volume: 1.64 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.13 (1,077.9% Upside)

$0.52-2.26: $98.39 million1.64 million sharesBuy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$6.13 (1,077.9% Upside)

Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

#3 – BIOLASE

NASDAQ:BIOL
Stock Price: $0.49

(-$0.02)

PE Ratio: -0.14
Market Cap: $3.76 million
Average Trading Volume: 786,619 shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.50 (1,852.7% Upside)

$0.49-0.14: $3.76 million786,619 sharesBuy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$9.50 (1,852.7% Upside)

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.

#4 – Verastem

NASDAQ:VSTM
Stock Price: $0.51

(-$0.01)

PE Ratio: -1.30
Market Cap: $106.62 million
Average Trading Volume: 857,045 shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.00 (885.2% Upside)

$0.51-1.30: $106.62 million857,045 sharesBuy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$5.00 (885.2% Upside)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

#5 – Leap Therapeutics

NASDAQ:LPTX
Stock Price: $0.56

(-$0.01)

PE Ratio: -1.20
Market Cap: $55.70 million
Average Trading Volume: 816,795 shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.00 (433.3% Upside)

$0.56-1.20: $55.70 million816,795 sharesBuy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$3.00 (433.3% Upside)

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

#6 – Surface Oncology

NASDAQ:SURF
Stock Price: $0.71

(+$0.05)

PE Ratio: -0.57
Market Cap: $42.87 million
Average Trading Volume: 241,879 shares
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.60 (832.1% Upside)

$0.71-0.57: $42.87 million241,879 sharesBuy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$6.60 (832.1% Upside)

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

#7 – X4 Pharmaceuticals

NASDAQ:XFOR
Stock Price: $0.97

(+$0.03)

PE Ratio: -0.34
Market Cap: $66.99 million
Average Trading Volume: 664,056 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.86 (608.7% Upside)

$0.97-0.34: $66.99 million664,056 sharesBuy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$6.86 (608.7% Upside)

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

#8 – Pear Therapeutics

NASDAQ:PEAR
Stock Price: $1.00

(+$0.01)

PE Ratio: -4.54
Market Cap: $139.89 million
Average Trading Volume: 187,154 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.25 (525.6% Upside)

$1.00-4.54: $139.89 million187,154 sharesBuy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$6.25 (525.6% Upside)

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

#9 – Lightning eMotors

NYSE:ZEV
Stock Price: $0.64

(-$0.04)

PE Ratio: 1.35
Market Cap: $57.08 million
Average Trading Volume: 1.94 million shares
P/E Ratio: 1.4
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.10 (1,017.4% Upside)

$0.641.35: $57.08 million1.94 million shares1.4Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$7.10 (1,017.4% Upside)

Lightning eMotors, Inc. designs, manufactures, and sells zero-emission commercial fleet vehicles and powertrains to commercial fleets, large enterprises, original equipment manufacturers, and governments in the United States. It offers zero-emission class 3 to 7 battery electric and fuel cell electric vehicles. The company’s vehicles comprise cargo and passenger vehicles, school buses, ambulances, shuttle buses, work trucks, city buses, and motorcoaches. It also offers charging systems and charging infrastructure solutions for commercial medium duty vans and motorcoach fleets. The company was founded in 2008 and is headquartered in Loveland, Colorado.

#10 – Saipem

OTCMKTS:SAPMY
Stock Price: $0.31

(+$0.02)

PE Ratio: 0.95
Average Trading Volume: 74,941 shares
P/E Ratio: 1.0
Consensus Rating: Buy (7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.07 (1,234.5% Upside)

$0.310.9574,941 shares1.0Buy (7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$4.07 (1,234.5% Upside)

Saipem SpA provides integrated basic and detailed onshore engineering, procurement, project management, and construction services mainly to the oil and gas, complex civil and marine infrastructure, and environmental market sectors. It operates through the following business segments: Offshore Engineering and Construction; Onshore Engineering and Construction; Offshore Drilling; and Onshore Drilling. The Offshore Engineering and Construction segment includes platforms, pipelines, subsea field developments, MMO or Maintenance, Modification, and Operations activities, and the execution of large-scale offshore projects. The Onshore Engineering and Construction segment designs and constructs hydrocarbon production facilities, hydrocarbon treatment facilities, and large onshore treatment and transportation systems and facilities. The Offshore Drilling segment consists of a fleet of vessels for deep water, mid-water, high specifications jack-up, and standard jack-up operations. The Onshore Drilling segment comprises a fleet of drilling rigs for wells in Italy and abroad. The company was founded in 1957 and is headquartered in San Donato Milanese, Italy.

#11 – Affimed

NASDAQ:AFMD
Stock Price: $0.87

(-$0.04)

PE Ratio: -1.38
Market Cap: $107.35 million
Average Trading Volume: 1.42 million shares
Consensus Rating: Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.83 (570.7% Upside)

$0.87-1.38: $107.35 million1.42 million sharesBuy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$5.83 (570.7% Upside)

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient’s immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

#12 – Aquestive Therapeutics

NASDAQ:AQST
Stock Price: $0.79

(+$0.00)

PE Ratio: -0.48
Market Cap: $42.53 million
Average Trading Volume: 257,956 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.10 (1,058.9% Upside)

$0.79-0.48: $42.53 million257,956 sharesBuy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$9.10 (1,058.9% Upside)

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

#13 – Rigetti Computing

NASDAQ:RGTI
Stock Price: $0.74

(-$0.01)

Market Cap: $91.12 million
Average Trading Volume: 1.71 million shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.00 (305.1% Upside)

$0.74: $91.12 million1.71 million sharesBuy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$3.00 (305.1% Upside)

Rigetti Computing, Inc. operates as an integrated systems company. The company builds quantum computers and the superconducting quantum processors that power them. Its machines are integrated into various public, private, or hybrid clouds through its Quantum Cloud Services platform. The company was founded in 2013 and is based in Berkeley, California.

#14 – Ocugen

NASDAQ:OCGN
Stock Price: $1.00

(+$0.00)

PE Ratio: -2.86
Market Cap: $218.85 million
Average Trading Volume: 6.04 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.80 (380.1% Upside)

$1.00-2.86: $218.85 million6.04 million sharesBuy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)$4.80 (380.1% Upside)

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm’s modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

#15 – Science 37

NASDAQ:SNCE
Stock Price: $0.31

(-$0.02)

PE Ratio: -0.62
Market Cap: $36.45 million
Average Trading Volume: 597,343 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.75 (1,100.4% Upside)

$0.31-0.62: $36.45 million597,343 sharesBuy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$3.75 (1,100.4% Upside)

Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

#16 – Petrofac

OTCMKTS:POFCY
Stock Price: $0.48
Market Cap: $502.29 million
Average Trading Volume: 12,497 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $140.00 (28,951.7% Upside)

$0.48: $502.29 million12,497 sharesBuy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$140.00 (28,951.7% Upside)

Petrofac Ltd. engages in the provision of services to the oil and gas production and processing industry. It offers engineering and construction; operations and maintenance; and training and competence. The firm operates through the following segments: Engineering and Construction; Engineering and Production Services; and Integrated Energy Services. The Engineering and Construction segment provides fixed-price engineering, procurement and construction project execution services and reimbursable engineering, procurement and construction management services to the onshore and offshore oil and gas industry. The Engineering and Production Services segment includes reimbursable engineering and production services activities to the oil and gas industry. The Integrated Energy Services segment focuses on delivering value from the existing asset portfolio. The company was founded in 1981 and is headquartered in St. Helier, the United Kingdom.

#17 – Harpoon Therapeutics

NASDAQ:HARP
Stock Price: $0.76

(-$0.01)

PE Ratio: -0.35
Market Cap: $25.18 million
Average Trading Volume: 551,419 shares
Consensus Rating: Buy (7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.25 (984.8% Upside)

$0.76-0.35: $25.18 million551,419 sharesBuy (7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)$8.25 (984.8% Upside)

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

#18 – Inseego

NASDAQ:INSG
Stock Price: $0.88

(-$0.01)

PE Ratio: -1.42
Market Cap: $95.03 million
Average Trading Volume: 636,566 shares
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.00 (581.0% Upside)

$0.88-1.42: $95.03 million636,566 sharesBuy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$6.00 (581.0% Upside)

Inseego Corp. engages in the business of communication equipment. The firm’s products include mobile hotspots, industrial gateways and routers, home and enterprise routers, industrial USB modems, and telematics and mobile tracking hardware devices. Its SaaS platforms include Ctrack, an asset tracking and management solution that delivers business intelligence for fleets used in various verticals, including aviation, construction, government, and transport, and Device Management Solutions, a hosted subscription management platform. The company was founded on April 26, 1996 and is headquartered in Alpharetta, GA.

#19 – Motus GI

NASDAQ:MOTS
Stock Price: $0.89

(-$0.03)

PE Ratio: -0.12
Market Cap: $2.67 million
Average Trading Volume: 107,607 shares
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.81 (553.9% Upside)

$0.89-0.12: $2.67 million107,607 sharesBuy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$5.81 (553.9% Upside)

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.

#20 – Assura

OTCMKTS:ARSSF
Stock Price: $0.63
Average Trading Volume: 9,023 shares
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $66.00 (10,376.2% Upside)

$0.639,023 sharesBuy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$66.00 (10,376.2% Upside)

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 30 September 2020, Assura’s property portfolio was valued at £2,259 million.

#21 – Marathon Gold

OTCMKTS:MGDPF
Stock Price: $0.64
Average Trading Volume: 100,300 shares
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.32 (261.5% Upside)

$0.64100,300 sharesBuy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$2.32 (261.5% Upside)

Marathon Gold Corp. engages in the acquisition, exploration, and development of precious and base metal prospects. It focuses on Valentine Gold Project located in Newfoundland and Labrador, Canada. The company was founded on December 3, 2009 and is headquartered in Toronto, Canada.

#22 – Galiano Gold

NYSEMKT:GAU
Stock Price: $0.52

(+$0.01)

PE Ratio: -1.53
Market Cap: $116.99 million
Average Trading Volume: 375,044 shares
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.14 (119.2% Upside)

$0.52-1.53: $116.99 million375,044 sharesBuy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$1.14 (119.2% Upside)

Galiano Gold Inc. engages in the exploration, development, and production of gold properties. The company’s primary asset is the Asanko Gold Mine located in Ghana, West Africa. The company was formerly known as Asanko Gold Inc. and changed its name to Galiano Gold Inc. in May 2020. Galiano Gold Inc. was incorporated in 1999 and is headquartered in Vancouver, Canada.

#23 – Greenlane

NASDAQ:GNLN
Stock Price: $0.37

(-$0.00)

PE Ratio: -0.02
Market Cap: $5.87 million
Average Trading Volume: 493,653 shares
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $21.75 (5,805.5% Upside)

$0.37-0.02: $5.87 million493,653 sharesBuy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)$21.75 (5,805.5% Upside)

Greenlane Holdings, Inc. distributes and supplies vaporization products and accessories for vape shops and dispensaries. The firm offers packaging, rolling papers, grinders, glass products, and smoking accessories. The company was founded by Aaron LoCascio and Adam Schoenfeld in 2005 and is headquartered in Boca Raton, FL.

#24 – Compugen

NASDAQ:CGEN
Stock Price: $0.79

(-$0.00)

PE Ratio: -1.98
Market Cap: $68.45 million
Average Trading Volume: 584,184 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $6.20 (684.7% Upside)

$0.79-1.98: $68.45 million584,184 sharesBuy (5 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)$6.20 (684.7% Upside)

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

#25 – Hookipa Pharma

NASDAQ:HOOK
Stock Price: $0.92

(+$0.06)

PE Ratio: -0.60
Market Cap: $50.33 million
Average Trading Volume: 211,229 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $7.25 (688.0% Upside)

$0.92-0.60: $50.33 million211,229 sharesBuy (4 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)$7.25 (688.0% Upside)

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.